ArticleCurrent microbiology2026
Enhancing Antibiotic Efficacy with Curcumin: A Novel Approach To Combat Multidrug-Resistant Acinetobacter Baumannii.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant (MDR) Acinetobacter baumannii is a major healthcare-associated pathogen with limited treatment options, and the ongoing rise of antibiotic resistance necessitates alternative therapeutic strategies. Curcumin, a bioactive compound derived from Curcuma longa, has demonstrated antimicrobial properties. This study evaluated the in vitro antibacterial activity of curcumin in combination with ceftazidime, imipenem, gentamicin, and ciprofloxacin against clinical MDR A. baumannii isolates. Forty MDR A. baumannii clinical isolates were collected, and their antibiotic susceptibility was confirmed using the Kirby-Bauer disk diffusion method. Broth microdilution assays determined the minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of curcumin and each antibiotic; synergistic interactions were evaluated using checkerboard assays. All isolates were resistant to ceftazidime, imipenem, gentamicin, and ciprofloxacin. In broth microdilution, curcumin alone exhibited a MIC range of 625–2500 µg/mL, while MIC ranges for ceftazidime, imipenem, gentamicin, and ciprofloxacin were 32–512, 8–128, 16–512, and 32–128 µg/mL, respectively. Checkerboard assays revealed synergistic interactions (fractional inhibitory concentration index ≤ 0.5) between curcumin and each antibiotic, with synergy observed in 90% of isolates for curcumin–imipenem, 87.5% for curcumin–ciprofloxacin, 80% for curcumin–ceftazidime, and 72.5% for curcumin–gentamicin. No antagonistic effects were observed. These findings demonstrate that curcumin can potentiate the activity of antibiotics against MDR A. baumannii in vitro; however, due to curcumin’s high concentration requirements and limited systemic bioavailability, further pharmacokinetic/pharmacodynamic studies and optimized formulation strategies are needed to assess its clinical potential.
Indexed as
Identifiers
41706160What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.